GSK plc Reports Total Voting Rights and Capital
Ticker: GLAXF · Form: 6-K · Filed: Nov 1, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, capital, voting-rights
TL;DR
GSK plc updated its total voting rights and capital as of Oct 31, 2024.
AI Summary
GSK plc is reporting its total voting rights and capital as of October 31, 2024, in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The company, formerly known as GlaxoSmithKline PLC, is providing this update for the month of November 2024.
Why It Matters
This filing provides transparency on the company's share capital and voting rights, which is important for investors to understand the ownership structure and potential influence on corporate decisions.
Risk Assessment
Risk Level: low — This is a routine disclosure of share capital and voting rights, with no new financial or operational information that would typically indicate higher risk.
Key Players & Entities
- GSK plc (company) — Registrant
- GlaxoSmithKline PLC (company) — Former company name
- October 31, 2024 (date) — Reporting date for share capital
- November 2024 (date) — Reporting month
- Financial Conduct Authority (company) — Regulator
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to notify the market of GSK plc's total voting rights and capital as of October 31, 2024, in compliance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
What was GSK plc's former name?
GSK plc was formerly known as GlaxoSmithKline PLC.
As of what date is the company reporting its issued share capital?
The company is reporting its issued share capital as of October 31, 2024.
Which rule requires GSK plc to make this disclosure?
GSK plc is making this disclosure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
What is the principal executive office address of GSK plc?
The principal executive office address of GSK plc is 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 319 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-11-01 11:21:27
Filing Documents
- a6559k.htm (6-K) — 16KB
- 0001654954-24-013610.txt ( ) — 17KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: November 01, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc